{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:27:10Z","timestamp":1776212830664,"version":"3.50.1"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1038\/s41585-024-00878-8","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T16:01:52Z","timestamp":1715097712000},"page":"754-760","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Elevated periprostatic androgens, sneaky testosterone and its implications"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3550-2735","authenticated-orcid":false,"given":"Masoud","family":"Bitaraf","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ranjith","family":"Ramasamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanoj","family":"Punnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1281-3474","authenticated-orcid":false,"given":"Nima","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,5,7]]},"reference":[{"key":"878_CR1","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1126\/science.7010602","volume":"211","author":"JD Wilson","year":"1981","unstructured":"Wilson, J. D., George, F. W. & Griffin, J. E. The hormonal control of sexual development. Science 211, 1278\u20131284 (1981).","journal-title":"Science"},{"key":"878_CR2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0303-7207(92)90004-P","volume":"88","author":"JP Deslypere","year":"1992","unstructured":"Deslypere, J. P., Young, M., Wilson, J. D. & McPhaul, M. J. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTV-CAT reporter gene. Mol. Cell Endocrinol. 88, 15\u201322 (1992).","journal-title":"Mol. Cell Endocrinol."},{"key":"878_CR3","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1200\/JCO.23.00433","volume":"41","author":"C Dai","year":"2023","unstructured":"Dai, C., Dehm, S. M. & Sharifi, N. Targeting the androgen signaling axis in prostate cancer. J. Clin. Oncol. 41, 4267\u20134278 (2023).","journal-title":"J. Clin. Oncol."},{"key":"878_CR4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1146\/annurev-med-051418-060357","volume":"71","author":"RJ Auchus","year":"2020","unstructured":"Auchus, R. J. & Sharifi, N. Sex hormones and prostate cancer. Annu. Rev. Med. 71, 33\u201345 (2020).","journal-title":"Annu. Rev. Med."},{"key":"878_CR5","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/j.juro.2016.06.091","volume":"196","author":"TS Beveridge","year":"2016","unstructured":"Beveridge, T. S. et al. Retroperitoneal lymph node dissection: anatomical and technical considerations from a cadaveric study. J. Urol. 196, 1764\u20131771 (2016).","journal-title":"J. Urol."},{"key":"878_CR6","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","volume":"16","author":"SY Ku","year":"2019","unstructured":"Ku, S. Y., Gleave, M. E. & Beltran, H. Towards precision oncology in advanced prostate cancer. Nat. Rev. Urol. 16, 645\u2013654 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"878_CR7","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1172\/JCI112673","volume":"78","author":"SJ Winters","year":"1986","unstructured":"Winters, S. J. & Troen, P. Testosterone and estradiol are co-secreted episodically by the human testis. J. Clin. Invest. 78, 870\u2013873 (1986).","journal-title":"J. Clin. Invest."},{"key":"878_CR8","doi-asserted-by":"crossref","DOI":"10.1172\/JCI171117","volume":"133","author":"M Alyamani","year":"2023","unstructured":"Alyamani, M. et al. Elevated periprostatic venous testosterone correlates with prostate cancer progression after radical prostatectomy. J. Clin. Invest. 133, e171117 (2023).","journal-title":"J. Clin. Invest."},{"key":"878_CR9","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1002\/cncr.25075","volume":"116","author":"TJ Walsh","year":"2010","unstructured":"Walsh, T. J. et al. Increased risk of high\u2010grade prostate cancer among infertile men. Cancer 116, 2140\u20132147 (2010).","journal-title":"Cancer"},{"key":"878_CR10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrurol.2012.198","volume":"10","author":"A Hamada","year":"2013","unstructured":"Hamada, A., Esteves, S. C. & Agarwal, A. Insight into oxidative stress in varicocele-associated male infertility: part 2. Nat. Rev. Urol. 10, 26\u201337 (2013).","journal-title":"Nat. Rev. Urol."},{"key":"878_CR11","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4103\/1008-682X.172640","volume":"18","author":"B Alsaikhan","year":"2016","unstructured":"Alsaikhan, B., Alrabeeah, K., Delouya, G. & Zini, A. Epidemiology of varicocele. Asian J. Androl. 18, 179\u2013181 (2016).","journal-title":"Asian J. Androl."},{"key":"878_CR12","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s00345-004-0421-0","volume":"22","author":"G Liguori","year":"2004","unstructured":"Liguori, G. et al. Color doppler ultrasound investigation of varicocele. World J. Urol. 22, 378\u2013381 (2004).","journal-title":"World J. Urol."},{"key":"878_CR13","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrurol.2017.98","volume":"14","author":"CFS Jensen","year":"2017","unstructured":"Jensen, C. F. S. et al. Varicocele and male infertility. Nat. Rev. Urol. 14, 523\u2013533 (2017).","journal-title":"Nat. Rev. Urol."},{"key":"878_CR14","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.juro.2008.06.048","volume":"180","author":"H Sakamoto","year":"2008","unstructured":"Sakamoto, H. & Ogawa, Y. Is varicocele associated with underlying venous abnormalities? Varicocele and the prostatic venous plexus. J. Urol. 180, 1427\u20131431 (2008).","journal-title":"J. Urol."},{"key":"878_CR15","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.eururo.2006.11.010","volume":"51","author":"D Tilki","year":"2007","unstructured":"Tilki, D. et al. The complex structure of the smooth muscle layer of spermatic veins and its potential role in the development of varicocele testis. Eur. Urol. 51, 1402\u20131409 (2007).","journal-title":"Eur. Urol."},{"key":"878_CR16","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1002\/pros.24051","volume":"80","author":"Y Gat","year":"2020","unstructured":"Gat, Y., Joshua, S., Vuk-Pavlovic, S. & Goren, M. Paying the price for standing tall: fluid mechanics of prostate pathology. Prostate 80, 1297\u20131303 (2020).","journal-title":"Prostate"},{"key":"878_CR17","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/j.tvir.2014.02.002","volume":"17","author":"CM Black","year":"2014","unstructured":"Black, C. M. Anatomy and physiology of the lower-extremity deep and superficial veins. Tech. Vasc. Interv. Radiol. 17, 68\u201373 (2014).","journal-title":"Tech. Vasc. Interv. Radiol."},{"key":"878_CR18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1439-0272.2009.00972.x","volume":"41","author":"Y Gat","year":"2009","unstructured":"Gat, Y., Joshua, S. & Gornish, M. G. Prostate cancer: a newly discovered route for testosterone to reach the prostate : treatment by super-selective intraprostatic androgen deprivation. Andrologia 41, 305\u2013315 (2009).","journal-title":"Andrologia"},{"key":"878_CR19","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0022-5347(05)67812-3","volume":"163","author":"MA Hoffman","year":"2000","unstructured":"Hoffman, M. A., DeWOLF, W. C. & Morgentaler, A. Is low serum free testosterone a marker for high grade prostate cancer? J. Urol. 163, 824\u2013827 (2000).","journal-title":"J. Urol."},{"key":"878_CR20","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1001\/jama.1996.03540230054035","volume":"276","author":"A Morgentaler","year":"1996","unstructured":"Morgentaler, A., Bruning, C. O. 3rd & DeWolf, W. C. Occult prostate cancer in men with low serum testosterone levels. JAMA 276, 1904\u20131906 (1996).","journal-title":"JAMA"},{"key":"878_CR21","doi-asserted-by":"crossref","DOI":"10.1111\/and.12992","volume":"50","author":"M Goren","year":"2018","unstructured":"Goren, M. & Gat, Y. Varicocele is the root cause of BPH: destruction of the valves in the spermatic veins produces elevated pressure which diverts undiluted testosterone directly from the testes to the prostate. Andrologia 50, e12992 (2018).","journal-title":"Andrologia"},{"key":"878_CR22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.urology.2005.03.062","volume":"66","author":"BK Canales","year":"2005","unstructured":"Canales, B. K. et al. Prevalence and effect of varicoceles in an elderly population. Urology 66, 627\u2013631 (2005).","journal-title":"Urology"},{"key":"878_CR23","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/13685538.2018.1465913","volume":"22","author":"H Besiroglu","year":"2019","unstructured":"Besiroglu, H., Otunctemur, A., Dursun, M. & Ozbek, E. The prevalence and severity of varicocele in adult population over the age of forty years old: a cross-sectional study. Aging Male 22, 207\u2013213 (2019).","journal-title":"Aging Male"},{"key":"878_CR24","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1439-0272.2007.00766.x","volume":"39","author":"U Levinger","year":"2007","unstructured":"Levinger, U., Gornish, M., Gat, Y. & Bachar, G. N. Is varicocele prevalence increasing with age? Andrologia 39, 77\u201380 (2007).","journal-title":"Andrologia"},{"key":"878_CR25","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0022-5347(17)38450-1","volume":"145","author":"MM Wishahi","year":"1991","unstructured":"Wishahi, M. M. Detailed anatomy of the internal spermatic vein and the ovarian vein. Human cadaver study and operative spermatic venography: clinical aspects. J. Urol. 145, 780\u2013784 (1991).","journal-title":"J. Urol."},{"key":"878_CR26","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/01485019308987738","volume":"30","author":"N Sofikitis","year":"1993","unstructured":"Sofikitis, N., Dritsas, K., Miyagawa, I. & Koutselinis, A. Anatomical characteristics of the left testicular venous system in man. Arch. Androl. 30, 79\u201385 (1993).","journal-title":"Arch. Androl."},{"key":"878_CR27","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s00345-008-0352-2","volume":"27","author":"M Iafrate","year":"2009","unstructured":"Iafrate, M. et al. Varicocele is associated with an increase of connective tissue of the pampiniform plexus vein wall. World J. Urol. 27, 363\u2013369 (2009).","journal-title":"World J. Urol."},{"key":"878_CR28","volume":"19","author":"R Li","year":"2021","unstructured":"Li, R., Liu, J., Li, Y. & Wang, Q. Effect of somatometric parameters on the prevalence and severity of varicocele: a systematic review and meta-analysis. Reprod. Biol. Endocrinol. 19, 11 (2021).","journal-title":"Reprod. Biol. Endocrinol."},{"key":"878_CR29","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1158\/1055-9965.EPI-08-0342","volume":"17","author":"L Zuccolo","year":"2008","unstructured":"Zuccolo, L. et al. Height and prostate cancer risk: a large nested case-control study (ProtecT) and meta-analysis. Cancer Epidemiol. Biomark. Prev. 17, 2325\u20132336 (2008).","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"878_CR30","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/bjc.2017.231","volume":"117","author":"A Lophatananon","year":"2017","unstructured":"Lophatananon, A. et al. Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium. Br. J. Cancer 117, 734\u2013743 (2017).","journal-title":"Br. J. Cancer"},{"key":"878_CR31","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1093\/ije\/dys086","volume":"41","author":"Emerging Risk Factors Collaboration.","year":"2012","unstructured":"Emerging Risk Factors Collaboration. Adult height and the risk of cause-specific death and vascular morbidity in 1 million people: individual participant meta-analysis. Int. J. Epidemiol. 41, 1419\u20131433 (2012).","journal-title":"Int. J. Epidemiol."},{"key":"878_CR32","first-page":"293","volume":"1","author":"C Huggins","year":"1941","unstructured":"Huggins, C. & Hodges, C. V. Studies on prostatic cancer. Cancer res. 1, 293\u2013297 (1941).","journal-title":"Cancer res."},{"key":"878_CR33","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1464-410X.2010.10030.x","volume":"108","author":"C Tanrikut","year":"2011","unstructured":"Tanrikut, C. et al. Varicocele as a risk factor for androgen deficiency and effect of repair. BJU Int. 108, 1480\u20131484 (2011).","journal-title":"BJU Int."},{"key":"878_CR34","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrurol.2012.175","volume":"9","author":"KH Chang","year":"2012","unstructured":"Chang, K. H. & Sharifi, N. Prostate cancer-from steroid transformations to clinical translation. Nat. Rev. Urol. 9, 721\u2013724 (2012).","journal-title":"Nat. Rev. Urol."},{"key":"878_CR35","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/j.1939-4640.1984.tb02388.x","volume":"5","author":"S Ando","year":"1984","unstructured":"Ando, S. et al. Physiopathologic aspects of Leydig cell function in varicocele patients. J. Androl. 5, 163\u2013170 (1984).","journal-title":"J. Androl."},{"key":"878_CR36","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.urology.2008.03.035","volume":"72","author":"YQ Zheng","year":"2008","unstructured":"Zheng, Y. Q. et al. The effects of artery-ligating and artery-preserving varicocelectomy on the ipsilateral testes in rats. Urology 72, 1179\u20131184 (2008).","journal-title":"Urology"},{"key":"878_CR37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1439-0272.2008.00883.x","volume":"40","author":"Y Gat","year":"2008","unstructured":"Gat, Y., Gornish, M., Heiblum, M. & Joshua, S. Reversal of benign prostate hyperplasia by selective occlusion of impaired venous drainage in the male reproductive system: novel mechanism, new treatment. Andrologia 40, 273\u2013281 (2008).","journal-title":"Andrologia"},{"key":"878_CR38","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/j.1939-4640.2001.tb02224.x","volume":"22","author":"JP Jarow","year":"2001","unstructured":"Jarow, J. P., Chen, H., Rosner, T. W., Trentacoste, S. & Zirkin, B. R. Assessment of the androgen environment within the human testis: minimally invasive method to obtain intratesticular fluid. J. Androl. 22, 640\u2013645 (2001).","journal-title":"J. Androl."},{"key":"878_CR39","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2164\/jandrol.04100","volume":"26","author":"JP Jarow","year":"2005","unstructured":"Jarow, J. P., Wright, W. W., Brown, T. R., Yan, X. & Zirkin, B. R. Bioactivity of androgens within the testes and serum of normal men. J. Androl. 26, 343\u2013348 (2005).","journal-title":"J. Androl."},{"key":"878_CR40","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1111\/and.12546","volume":"48","author":"H Han","year":"2016","unstructured":"Han, H. et al. Significant alterations of serum hormone levels in the spermatic vein plexus of patients with varicoceles. Andrologia 48, 1108\u20131112 (2016).","journal-title":"Andrologia"},{"key":"878_CR41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1097\/JU.0000000000001016","volume":"204","author":"TFN Lima","year":"2020","unstructured":"Lima, T. F. N., Patel, P., Blachman-Braun, R., Madhusoodanan, V. & Ramasamy, R. Serum 17-hydroxyprogesterone is a potential biomarker for evaluating intratesticular testosterone. J. Urol. 204, 551\u2013556 (2020).","journal-title":"J. Urol."},{"key":"878_CR42","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1210\/er.2018-00258","volume":"40","author":"M Engels","year":"2019","unstructured":"Engels, M. et al. Testicular adrenal rest tumors: current insights on prevalence, characteristics, origin, and treatment. Endocr. Rev. 40, 973\u2013987 (2019).","journal-title":"Endocr. Rev."},{"key":"878_CR43","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/aja.2010.111","volume":"13","author":"DY Luo","year":"2011","unstructured":"Luo, D. Y., Yang, G., Liu, J. J., Yang, Y. R. & Dong, Q. Effects of varicocele on testosterone, apoptosis and expression of StAR mRNA in rat Leydig cells. Asian J. Androl. 13, 287\u2013291 (2011).","journal-title":"Asian J. Androl."},{"key":"878_CR44","first-page":"133","volume":"3","author":"AP Bernstein","year":"2022","unstructured":"Bernstein, A. P. & Najari, B. B. Varicocele treatment and serum testosterone. Androgens: Clin. Res. Ther. 3, 133\u2013137 (2022).","journal-title":"Androgens: Clin. Res. Ther."},{"key":"878_CR45","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3892\/ol.2017.5616","volume":"13","author":"H Tu","year":"2017","unstructured":"Tu, H. et al. Low serum testosterone is associated with tumor aggressiveness and poor prognosis in prostate cancer. Oncol. Lett. 13, 1949\u20131957 (2017).","journal-title":"Oncol. Lett."},{"key":"878_CR46","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s11154-022-09730-z","volume":"23","author":"K Wel\u00e9n","year":"2022","unstructured":"Wel\u00e9n, K., Damber, J.-E. J. R. I. E. & Disorders, M. Androgens, aging, and prostate health. Rev. Endocr. Metab. Disord. 23, 1221\u20131231 (2022).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"878_CR47","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/ijir.2008.55","volume":"20","author":"CG Roehrborn","year":"2008","unstructured":"Roehrborn, C. G. Pathology of benign prostatic hyperplasia. Int. J. Impot. Res. 20, S11\u2013S18 (2008).","journal-title":"Int. J. Impot. Res."},{"key":"878_CR48","doi-asserted-by":"crossref","first-page":"16032","DOI":"10.1038\/nrdp.2016.32","volume":"2","author":"B Chughtai","year":"2016","unstructured":"Chughtai, B. et al. Benign prostatic hyperplasia. Nat. Rev. Dis. Prim. 2, 16032 (2016).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"878_CR49","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/S0022-5347(17)49698-4","volume":"132","author":"SJ Berry","year":"1984","unstructured":"Berry, S. J., Coffey, D. S., Walsh, P. C. & Ewing, L. L. The development of human benign prostatic hyperplasia with age. J. Urol. 132, 474\u2013479 (1984).","journal-title":"J. Urol."},{"key":"878_CR50","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2010-1865","volume":"96","author":"ST Page","year":"2011","unstructured":"Page, S. T. et al. Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial. J. Clin. Endocrinol. Metab. 96, 430\u2013437 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"878_CR51","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1464-410X.2011.10652.x","volume":"109","author":"TM van der Sluis","year":"2012","unstructured":"van der Sluis, T. M. et al. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer. BJU Int. 109, 183\u2013188 (2012).","journal-title":"BJU Int."},{"key":"878_CR52","doi-asserted-by":"crossref","first-page":"6351","DOI":"10.1158\/1078-0432.CCR-17-1313","volume":"23","author":"C Dai","year":"2017","unstructured":"Dai, C. et al. Direct metabolic interrogation of dihydrotestosterone biosynthesis from adrenal precursors in primary prostatectomy tissues. Clin. Cancer Res. 23, 6351\u20136362 (2017).","journal-title":"Clin. Cancer Res."},{"key":"878_CR53","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/S0090-4295(03)00045-1","volume":"61","author":"C Carson III","year":"2003","unstructured":"Carson, C. III & Rittmaster, R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61, 2\u20137 (2003).","journal-title":"Urology"},{"key":"878_CR54","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1006\/excr.1996.0013","volume":"222","author":"IY Kim","year":"1996","unstructured":"Kim, I. Y. et al. Modulation of sensitivity to transforming growth factor-beta 1 (TGF-beta 1) and the level of type II TGF-beta receptor in LNCaP cells by dihydrotestosterone. Exp. Cell Res. 222, 103\u2013110 (1996).","journal-title":"Exp. Cell Res."},{"key":"878_CR55","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/1097-0045(2000)45:9+<4::AID-PROS3>3.0.CO;2-Q","volume":"9","author":"CS Foster","year":"2000","unstructured":"Foster, C. S. Pathology of benign prostatic hyperplasia. Prostate Suppl. 9, 4\u201314 (2000).","journal-title":"Prostate Suppl."},{"key":"878_CR56","first-page":"24","volume":"32","author":"K Griffiths","year":"1997","unstructured":"Griffiths, K., Morton, M. S. & Nicholson, R. I. Androgens, androgen receptors, antiandrogens and the treatment of prostate cancer. Eur. Urol. 32, 24\u201340 (1997).","journal-title":"Eur. Urol."},{"key":"878_CR57","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/pros.2990050510","volume":"5","author":"JT Isaacs","year":"1984","unstructured":"Isaacs, J. T. Antagonistic effect of androgen on prostatic cell death. Prostate 5, 545\u2013557 (1984).","journal-title":"Prostate"},{"key":"878_CR58","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1046\/j.1464-410x.2001.00103.x","volume":"87","author":"Y Niu","year":"2001","unstructured":"Niu, Y. et al. Proliferation and differentiation of prostatic stromal cells. BJU Int. 87, 386\u2013393 (2001).","journal-title":"BJU Int."},{"key":"878_CR59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ajur.2017.11.005","volume":"5","author":"EH Kim","year":"2018","unstructured":"Kim, E. H., Brockman, J. A. & Andriole, G. L. The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Asian J. Urol. 5, 28\u201332 (2018).","journal-title":"Asian J. Urol."},{"key":"878_CR60","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1210\/jc.2016-1483","volume":"101","author":"A Thirumalai","year":"2016","unstructured":"Thirumalai, A. et al. Stable intraprostatic dihydrotestosterone in healthy medically castrate men treated with exogenous testosterone. J. Clin. Endocrinol. Metab. 101, 2937\u20132944 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"878_CR61","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2010.05.033","volume":"184","author":"JK Parsons","year":"2010","unstructured":"Parsons, J. K., Palazzi-Churas, K., Bergstrom, J. & Barrett-Connor, E. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: the Rancho Bernardo Study. J. Urol. 184, 1040\u20131044 (2010).","journal-title":"J. Urol."},{"key":"878_CR62","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/j.1464-410X.2009.09090.x","volume":"105","author":"MD Trifiro","year":"2010","unstructured":"Trifiro, M. D. et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int. 105, 1554\u20131559 (2010).","journal-title":"BJU Int."},{"key":"878_CR63","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1093\/aje\/kwn272","volume":"168","author":"AR Kristal","year":"2008","unstructured":"Kristal, A. R. et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol. 168, 1416\u20131424 (2008).","journal-title":"Am. J. Epidemiol."},{"key":"878_CR64","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/pros.1046","volume":"47","author":"G Schatzl","year":"2001","unstructured":"Schatzl, G. et al. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 47, 52\u201358 (2001).","journal-title":"Prostate"},{"key":"878_CR65","first-page":"3615","volume":"31","author":"C Kratzik","year":"2011","unstructured":"Kratzik, C. et al. Lower serum total testosterone is associated with lymph node metastases in a radical prostatectomy cohort study. Anticancer Res. 31, 3615\u20133618 (2011).","journal-title":"Anticancer Res."},{"key":"878_CR66","volume":"133","author":"X Li","year":"2023","unstructured":"Li, X. et al. BMX controls 3betaHSD1 and sex steroid biosynthesis in cancer. J. Clin. Invest. 133, e163498 (2023).","journal-title":"J. Clin. Invest."},{"key":"878_CR67","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1158\/0008-5472.CAN-09-0919","volume":"69","author":"KK Waltering","year":"2009","unstructured":"Waltering, K. K. et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 69, 8141\u20138149 (2009).","journal-title":"Cancer Res."},{"key":"878_CR68","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm972","volume":"10","author":"CD Chen","year":"2004","unstructured":"Chen, C. D. et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33\u201339 (2004).","journal-title":"Nat. Med."},{"key":"878_CR69","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","volume":"11","author":"MA Titus","year":"2005","unstructured":"Titus, M. A., Schell, M. J., Lih, F. B., Tomer, K. B. & Mohler, J. L. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin. Cancer Res. 11, 4653\u20134657 (2005).","journal-title":"Clin. Cancer Res."},{"key":"878_CR70","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","volume":"68","author":"RB Montgomery","year":"2008","unstructured":"Montgomery, R. B. et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68, 4447\u20134454 (2008).","journal-title":"Cancer Res."},{"key":"878_CR71","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1158\/0008-5472.CAN-05-4000","volume":"66","author":"M Stanbrough","year":"2006","unstructured":"Stanbrough, M. et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66, 2815\u20132825 (2006).","journal-title":"Cancer Res."},{"key":"878_CR72","doi-asserted-by":"crossref","first-page":"7121","DOI":"10.1158\/1078-0432.CCR-04-0913","volume":"10","author":"T Nishiyama","year":"2004","unstructured":"Nishiyama, T., Hashimoto, Y. & Takahashi, K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin. Cancer Res. 10, 7121\u20137126 (2004).","journal-title":"Clin. Cancer Res."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00878-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00878-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T14:05:41Z","timestamp":1732889141000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-024-00878-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,7]]},"references-count":72,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["878"],"URL":"https:\/\/doi.org\/10.1038\/s41585-024-00878-8","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,7]]},"assertion":[{"value":"4 April 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}